You searched for "CRISPR Therapeutics" - Page 2 of 3

Weekly reads: reprogramming hearing loss, heart disease, eye drops, sickle cell

April 30, 2023 / Professor Paul Knoepfler, Ph.D. / Leave a Comment

It’s mostly been a week of good and encouraging news in the regenerative medicine space including with gene therapies maybe with the exception of some eye drops warnings (more below). There’s realistic hope for an approved sickle cell disease soon. I also see some long-term positive news on hearing loss research. Hematopoietic stem cell transplant […]

Weekly reads: reprogramming hearing loss, heart disease, eye drops, sickle cell Read More »

2023 stem cell & regenerative medicine predictions

December 28, 2022 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Toward the end of each year, I make stem cell & regenerative medicine predictions for the coming year. It’s a fun tradition here on The Niche that goes way back. The stem cell field has changed dramatically as reflected in each year’s predictions. Here’s a list of past predictions with my grades of how they

2023 stem cell & regenerative medicine predictions Read More »

Grading my 21 stem cell & regenerative medicine predictions for 2021

December 22, 2021 / Professor Paul Knoepfler, Ph.D. / 3 Comments

The world of stem cell research and regenerative medicine is unpredictable but it’s fun to be a part of it and try to do predictions. Each year in late December or early January I make prognostications for the coming year for stem cell research and regenerative medicine. I made 21 such predictions for the current

Grading my 21 stem cell & regenerative medicine predictions for 2021 Read More »

Clade Therapeutics pursues universal cells for cancer therapy

November 4, 2021 / Professor Paul Knoepfler, Ph.D. / 2 Comments

Clade Therapeutics has been pursuing the idea of using gene-editing to make universally compatible cells. The potential here is big. What if you could make cloaked stem cells that could be used to produce cellular therapies that could be given to most patients without fear of immune rejection? Clade Therapeutics Boston Business Journal covers the

Clade Therapeutics pursues universal cells for cancer therapy Read More »

Stem cell therapy for diabetes updates: expected IPO, CRISPR, new pubs, more

June 22, 2021 / Professor Paul Knoepfler, Ph.D. / 3 Comments

The idea of stem cell therapy for diabetes is both exciting and in a way practical. By that I mean that there’s a good common sense foundation here. The idea of stem cell therapy for diabetes What do I mean? If medical researchers can replace lost beta cells in the pancreas using stem cell-produced beta

Stem cell therapy for diabetes updates: expected IPO, CRISPR, new pubs, more Read More »

21 Stem Cell Research & Regenerative Medicine 2021 Predictions

January 12, 2021 / Professor Paul Knoepfler, Ph.D. / 6 Comments

In any given field of biomedical science like stem cell research and regenerative medicine, it’s very useful if you can accurately predict the future. It seems, though, that predictions are far more difficult within the more exciting and rapidly-changing fields. The field of stem cells and regenerative medicine fits that bill. Past stem cell research

21 Stem Cell Research & Regenerative Medicine 2021 Predictions Read More »

Weekly recommended science reads: stem cells, CRISPR, cancer & more

March 1, 2020 / Professor Paul Knoepfler, Ph.D. / 1 Comment

CRISPR-for-muscular-dystrophy.-Zhang-et-al.-Science-2020.-Screenshot-of-Fig.-2-featured-image

There’s never enough time to get all of one’s science reading done, but we can try! It helps to have a list of “to-read” articles, whether actual research articles or media pieces. In the old days, I remember my mentors saying they literally had “piles” of journal articles on their coffee tables, bathrooms, bedrooms, etc.

ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more

September 25, 2019 / Professor Paul Knoepfler, Ph.D. / 9 Comments

ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We had a great chat about the science and how things are looking upbeat for the

ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more Read More »

Good final grades on my 20 x 2018 stem cell predictions

December 26, 2018 / Professor Paul Knoepfler, Ph.D. / 1 Comment

Each year I make a list of stem cell predictions for the following year and I’ll release my predictions for 2019 soon, but first I’m grading how my 20 predictions for 2018 turned out. It seems I did better than usual predicting what would happen this year. I only got a couple partial credit or

Good final grades on my 20 x 2018 stem cell predictions Read More »

Quick Q&A with ViaCyte CEO on CRISPR-stem cell work

September 19, 2018 / Professor Paul Knoepfler, Ph.D. / 4 Comments

VC-01-post-implant-final1-e1503703572933, viacyte

We heard this week about the encouraging news of a new CRISPR-stem cell collaboration between stem cell biotech ViaCyte and CRISPR Therapeutics. The goal of the team is to make genetically engineered pancreatic derivatives from stem cells that would have a unique immune stealthiness. If such an approach was successful, patients would not need to

Quick Q&A with ViaCyte CEO on CRISPR-stem cell work Read More »

Search Results for: "CRISPR Therapeutics"